We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Patient Guided Psychiatric Admissions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01133587
Recruitment Status : Completed
First Posted : May 31, 2010
Last Update Posted : April 4, 2017
Sponsor:
Information provided by (Responsible Party):
St. Olavs Hospital

Brief Summary:

To meet the requirement for increased patient involvement, several Community Mental Health Centres (CMHC) have initiated a service called "patient-guided admissions". The investigators will compare a group with "patient guided admission/self-referral to inpatient beds" with a group having treatment as usual.

It is expected that patients in the intervention group will experience more increased feeling of coping (patient activation) after 4 months and 12 months as a result of participating in "patient-guided admissions" than patients getting treatment as usual. In addition the total number of inpatient days either in the CMHC, psychiatric hospital or community rehabilitation centre is expected to be clearly lower in the intervention group than in the 'treatment-as-usual' group during one year after intake. Also the number of involuntary admissions either as inpatient or outpatient will be significant lower in the intervention group than the 'treatment-as-usual' group.The number of admissions in CMHC and psychiatric hospital, as well as the number of outpatient consultations in primary care, CMHC and psychiatric hospitals, will be lower in the intervention group than in the 'treatment-as-usual' group. Patients in the intervention group will experience improved mental health, increased feeling of coping (patient activation) and increased experience of recovery after 4 months and 12 months as a result of participating in "patient-guided admissions".


Condition or disease Intervention/treatment
Schizophrenia Bipolar Disorder Other: wait list control Behavioral: admissions contract

Detailed Description:

Participants will be patients with psychosis or bipolar disorders. Patients in the intervention group will have a contract on "self-referral to inpatient beds" for one year. They can call the CMHC directly and ask for a bed for until 5 nights.

The patients in the 'treatment-as-usual' group will follow common procedures by either contacting their general practitioner, emergency department or duty doctor, and they will be offered a "self-referral to inpatient bed" contract after a year if they satisfy the inclusion criteria.

Regardless of the participation in the intervention group, the patients can also be ordinary admitted during the project period by a doctor via regular procedures in both hospital and CMHC if there is a need for this. All admissions will appear in the register data.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Patient Guided Psychiatric Admissions (Self-referral to Inpatient Beds)
Study Start Date : May 2010
Primary Completion Date : December 2013
Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: admissions contract
contract regarding "patient-guided admissions"
Behavioral: admissions contract
contract regarding "patient-guided admissions" starting immediately
Active Comparator: wait list control
1 year on waiting list
Other: wait list control
Patient-guided admissions contract regarding "patient-guided admissions" starting a year after.



Primary Outcome Measures :
  1. Patient activation/coping [ Time Frame: 4 months ]
    Patient Activation Measure (PAM 13)

  2. Patient activation/coping [ Time Frame: 12 months ]
    Patient Activation Measure (PAM 13)


Secondary Outcome Measures :
  1. Number of admissions [ Time Frame: 12 months ]
    Number of admissions in CMHC, psychiatric hospital of community rehabilitation centre

  2. Total number of inpatient days [ Time Frame: 12 months ]
    Total number of inpatient days in CMHC, psychiatric hospital or community rehabilitation centre

  3. Number of outpatient consultations [ Time Frame: 12 months ]
    Number of outpatient consultations in primary care, in CMHC and psychiatric hospital

  4. Number of involuntary admissions [ Time Frame: 12 months ]
    Number of involuntary admissions either as inpatient or outpatient

  5. Symptoms/functioning and recovery [ Time Frame: 4 months ]
    Behavior and symptom identification scale (BASIS 32) and Recovery Assessment Scale (RAS 24)

  6. Symptoms/functioning and recovery [ Time Frame: 12 months ]
    Behavior and symptom identification scale (BASIS 32) and Recovery Assessment Scale (RAS 24)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • schizophrenia or bipolar disorder
  • long term care
  • established relationship with the ward

Exclusion Criteria:

  • extensive substance use problems
  • self-destructive behavior
  • not able to consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01133587


Locations
Norway
St.Olavs hospital, Psykisk helsevern, Nidaros DPS
Trondheim, Norway, 7440
Sponsors and Collaborators
St. Olavs Hospital
Investigators
Principal Investigator: Lasse Eriksen, PhD St. Olavs Hospital

Publications:
Responsible Party: St. Olavs Hospital
ClinicalTrials.gov Identifier: NCT01133587     History of Changes
Other Study ID Numbers: 2009/1704
2009/1704 ( Other Grant/Funding Number: St Olavs Hospital )
First Posted: May 31, 2010    Key Record Dates
Last Update Posted: April 4, 2017
Last Verified: March 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by St. Olavs Hospital:
Schizophrenia
bipolar disorder
Long term care
patient admission

Additional relevant MeSH terms:
Schizophrenia
Bipolar Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Bipolar and Related Disorders